| Titre | | nb de chargement | |
|---|
| Availability of Transgene's 2023 Universal Registration Document | | 293 | |
| Mise à disposition du document d'enregistrement universel 2023 de Transgene | | 330 | |
| Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 | | 381 | |
| Transgene et NEC présentent les premières données cliniques de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à lAACR 2024 | | 375 | |
| Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers | | 2 | |
| Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers | | 3 | |
| Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 | | 375 | |
| Transgene prévoit des avancées significatives sur son portefeuille d'immunothérapie en 2024 et étend sa visibilité financière jusqu'au 4ème trimestre 2025 | | 867 | |
| Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer | | 539 | |
| Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer comme Directrice des Ressources Humaines | | 1443 | |
| Investor Access Event - April 5, 2024 | | 48 | |
| Investor Access Event - 5 avril 2024 | | 48 | |
| Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands)- April 16, 2024 | | 48 | |
| Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands) - 16 avril, 2024 | | 48 | |
| Transgene Announces Upcoming Investor Meetings | | 469 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 391 | |
| Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024 | | 1617 | |
| Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l'AACR 2024 | | 870 | |
| Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 | | 591 | |
| Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l'essai clinique de Phase I/II du vaccin individualisé TG4050 | | 479 | |
| Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer | | 1938 | |
| Transgene annonce la nomination de James Wentworth comme Directeur du Business Development | | 957 | |
| Forum Oddo BHF - 15 & 16 janvier 2024 | | 72 | |
| Oddo BHF Forum - January 15 & 16, 2024 | | 72 | |
| Transgene Announces Financial Calendar for 2024 | | 1392 | |
| Transgene présente son calendrier de communication financière pour 2024 | | 832 | |
| Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050 | | 1037 | |
| Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancer | | 5310 | |
| Transgene Announces Upcoming Investor Meetings | | 5585 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 780 | |
| Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy | | 13265 | |
| Transgene renforce son équipe de direction pour accélérer sa stratégie de croissance | | 1813 | |
| Transgene reports business update and Q3 2023 financial position | | 8185 | |
| Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2023 | | 3186 | |
| Transgene and BioInvent - First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab) | | 14378 | |
| Transgene et BioInvent - Un premier patient traité dans la partie B de l'essai de Phase I évaluant le virus oncolytique BT-001 en combinaison avec KEYTRUDA®(pembrolizumab) | | 1400 | |
| Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024 | | 2211 | |
| Transgene fait progresser son portefeuille d'immunothérapies innovantes et étend sa visibilité financière jusqu'à fin 2024 | | 1949 | |
| 2023 Half-year results and business update | | 125 | |
| Résultats financiers du 1er semestre 2023 et point sur lactivité | | 125 | |
| Transgene Announces Upcoming Investor Meetings | | 5649 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 1438 | |
| Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma | | 141 | |
| Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma | | 141 | |
| Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers | | 141 | |
| Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers | | 141 | |
| Transgene receives $15.3 Million from the Sale of Securities Held for Sale | | 9637 | |
| Transgene encaisse 15,3 millions de dollars grâce à la cession d'actifs financiers destinés à la vente | | 1616 | |
| Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023 | | 4563 | |
| ASCO 2023 - Transgene et NEC présentent de nouvelles données sur TG4050 un vaccin individualisé contre le cancer, démontrant qu'il induit des réponses immunitaires contre les carcinomes de la tête et du cou | | 2825 | |
| Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023 | | 4400 | |
| ASCO 2023 - Transgene présente des données immunologiques démontrant que TG4001, un vaccin thérapeutique innovant contre le cancer, peut induire des réponses immunitaires contre les antigènes du HPV16 dans l'essai de Phase II en cours | | 2132 | |
| Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers | | 522 | |
| Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers | | 522 | |
| Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting | | 10426 | |
| Transgene présente des données sur ses deux vaccins thérapeutiques contre le cancer à l'ASCO 2023 | | 1856 | |
| Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors | | 12249 | |
| Transgene et BioInvent annoncent des résultats positifs pour l'essai de Phase Ia du virus oncolytique BT-001 dans le traitement des tumeurs solides | | 4496 | |
| Transgene provides business update and Q1 2023 financial position | | 12076 | |
| Transgene fait un point sur son activité et publie sa situation financière au premier trimestre 2023 | | 5617 | |
| Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer | | 4486 | |
| Transgene - Premier patient traité dans l'essai de Phase I évaluant TG6050, un virus oncolytique innovant armé avec de l'IL-12, dans le cancer du poumon non à petites cellules | | 1844 | |
| Transgene's Combined General Meeting of May 5, 2023 | | 8919 | |
| Assemblée Générale Mixte de Transgene du 5 mai 2023 | | 7031 | |
| Nouveau leadership pour accélérer le développement du portefeuille dimmunothérapies innovantes | | 522 | |
| New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio | | 522 | |
| Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio | | 3760 | |
| Transgene annonce un nouveau leadership pour accélérer le développement de son portefeuille dimmunothérapies innovantes | | 1358 | |
| New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 | | 32984 | |
| Présentation à l'AACR de nouvelles données montrant que le vaccin thérapeutique individualisé TG4050 de Transgene et NEC induit des réponses immunitaires fortes et spécifiques contre les tumeurs | | 10647 | |
| PoxSTG, a novel chimeric poxvirus with improved oncolytic potency | | 522 | |
| PoxSTG, a novel chimeric poxvirus with improved oncolytic potency | | 522 | |
| Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators | | 522 | |
| Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators | | 522 | |
| Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer | | 522 | |
| Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer | | 522 | |
| A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers | | 522 | |
| A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers | | 522 | |
| Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer | | 522 | |
| Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer | | 522 | |
| Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy | | 522 | |
| Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy | | 522 | |
| Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses | | 522 | |
| Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses | | 522 | |
| TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses | | 522 | |
| TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses | | 522 | |
| Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR | | 5242 | |
| Présentation à l'AACR de résultats précliniques montrant que TG6050, un virus oncolytique innovant, induit une régression tumorale grâce à l'activation des réponses immunitaires innées et adaptatives | | 1899 | |
| Transgene's Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director | | 18216 | |
| Le conseil d'administration de Transgene propose la nomination de Carol Stuckley, en tant que nouvelle administratrice indépendante | | 1786 | |
| Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023 | | 8374 | |
| Mise à disposition des documents préparatoires à l'Assemblée générale du 5 mai 2023 | | 2181 | |
| annonce kol event | | 522 | |
| annonceR&D | | 522 | |
| 2022 Full-year results and business update | | 522 | |
| Résultats annuels 2022 | | 522 | |
| Availability of Transgenes 2022 Universal Registration Document | | 7082 | |
| Mise à disposition du document d'enregistrement universel 2022 | | 1778 | |
| Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers | | 8005 | |
| Transgene organise un webinaire sur TG4050, un vaccin thérapeutique individualisé contre les cancers de la tête et du cou HPV négatifs | | 2550 | |
| Scientific advisors | | 523 | |
| Conseillers scientifiques | | 523 | |
| Scientific advisors | | 523 | |
| Conseillers scientifiques | | 523 | |
| Pedro Romero, MD | | 523 | |
| Pedro Romero, MD | | 523 | |
| John C. Bell, PhD | | 523 | |
| John C. Bell, PhD | | 523 | |
| Transgene Announces Upcoming Investor Meetings | | 3967 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 1258 | |
| Positive data on key clinical candidates delivered in 2022 - Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum | | 7037 | |
| Les données positives générées en 2022 avec les principaux candidats cliniques confortent les perspectives de Transgene pour 2023, dans un contexte porteur pour les vaccins thérapeutiques contre le cancer et les virus oncolytiques | | 3563 | |
| Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 | | 25018 | |
| Transgene présentera plusieurs posters soulignant le potentiel de son portefeuille d'immunothérapies à l'AACR 2023 | | 9934 | |
| Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors | | 5139 | |
| Transgene nomme John C. Bell et Pedro Romero en tant que Conseillers Scientifiques | | 1324 | |
| TG6050 | | 610 | |
| TG6050 | | 610 | |
| produits : TG6050 - en | | 610 | |
| produits : TG6050 | | 610 | |
| Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration | | 16185 | |
| Transgene reçoit l'autorisation de lancer un essai de Phase I avec TG6050, un virus oncolytique innovant armé avec de l'IL-12 et administré par voie intraveineuse | | 9290 | |
| Transgene announces Financial Calendar for 2023 | | 7227 | |
| Transgene présente son calendrier de communication financière pour 2023 | | 8312 | |
| Invest Securities Biomed Forum - January 30, 2024 | | 13059 | |
| Invest Securities Biomed Forum - 30 janvier 2024 | | 13059 | |
| 13th edition of the LifeSci Advisors Corporate Access Event - January 8 to 10, 2023 | | 13059 | |
| 13ème édition du LifeSci Advisors Corporate Access Event - 8 au 10 janvier 2024 | | 13059 | |
| Transgene Announces Upcoming Investor Meetings | | 19797 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 14204 | |
| __cf_bm | | 13059 | |
| vuid | | 13059 | |
| _pk_ses.1.9651 | | 13059 | |
| _pk_id.1.9651 | | 13059 | |
| JSESSIONID | | 13059 | |
| CookieLawInfoConsent | | 13059 | |
| viewed_cookie_policy | | 13059 | |
| cookielawinfo-checkbox-fonctionnels | | 13059 | |
| cookielawinfo-checkbox-cookies-externes | | 13059 | |
| cookielawinfo-checkbox-analytique | | 13059 | |
| cookielawinfo-checkbox-essentiels | | 13059 | |
| Transgene and BioInvent joint paper on BT-001 wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 | | 25045 | |
| Transgene et BioInvent remportent le prix du Meilleur Article dans la catégorie Immunothérapie oncolytique et locale décerné par le JITC, pour leurs travaux sur BT-001 | | 20156 | |
| Politique de confidentialité | | 14328 | |
| | 14328 | |
| | 14328 | |
| | 14328 | |
| Cookie policy | | 14328 | |
| privacy policy | | 14328 | |
| POLITIQUE DE CONFIDENTIALITE | | 14328 | |
